Treatment of portal systemic encephalopathy: standard and new treatments.
The management of hepatic encephalopathy should be considered accordingly with the precipitating factor and the type of encephalopathy. Ideally the therapeutic approach must be useful for both acute and chronic forms of encephalopathy. Current treatment of hepatic encephalopathy consists of certain well-established measures attempting to identify and treat the precipitating factors, and to reduce the intestinal nitrogenous compounds formation and absorption by dietary restriction or bowel-cleansing with catartics or antibiotics such as neomycin, metronidazol, etc. This review describes briefly several therapeutic modalities.
Marín
E
E
Instituto Nacional de la Nutrición Salador, Zubirán, México 14000, DF.
Uribe
M
M
D001971:Bromocriptine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003106:Colon / Q000382:microbiology; D004044:Dietary Proteins / Q000009:adverse effects; D004187:Disaccharides / Q000627:therapeutic use; D004311:Double-Blind Method; D004733:Enema; D018756:GABA Antagonists / Q000627:therapeutic use; D006471:Gastrointestinal Hemorrhage / Q000150:complications; D006501:Hepatic Encephalopathy / Q000178:diet therapy / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006801:Humans; D022124:Hyperammonemia / Q000150:complications; D054368:Laxatives / Q000627:therapeutic use; D007980:Levodopa / Q000627:therapeutic use; D008103:Liver Cirrhosis / Q000150:complications / Q000178:diet therapy; D044342:Malnutrition / Q000150:complications; D053858:Metabolic Networks and Pathways; D014674:Plant Proteins, Dietary / Q000627:therapeutic use; D020160:Sodium Benzoate / Q000627:therapeutic use; D015032:Zinc / Q000627:therapeutic use
D004044:Dietary Proteins; D004187:Disaccharides; D018756:GABA Antagonists; D054368:Laxatives; D014674:Plant Proteins, Dietary; D001971:Bromocriptine; D007980:Levodopa; D015032:Zinc; D020160:Sodium Benzoate